INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”
INVO Fertility (Nasdaq: NAYA) announced it will begin trading under the new symbol 'IVF' on April 28, 2025, following its strategic decision to separate its fertility and oncology businesses. The company, formerly known as NAYA Biosciences, will maintain its current CUSIP number.
CEO Steve Shum stated that the new ticker symbol reflects their focus on the fertility care market, particularly their strategy of building, acquiring, and operating fertility clinics in the United States. The company aims to expand access to innovative reproductive services and technologies, aligning with the recent U.S. Presidential executive order to reduce IVF costs and increase accessibility to fertility services.
INVO Fertility (Nasdaq: NAYA) ha annunciato che inizierà a essere quotata con il nuovo simbolo 'IVF' dal 28 aprile 2025, a seguito della decisione strategica di separare le sue attività nel settore della fertilità da quelle oncologiche. La società, precedentemente conosciuta come NAYA Biosciences, manterrà il suo attuale numero CUSIP.
Il CEO Steve Shum ha dichiarato che il nuovo simbolo di borsa riflette il loro focus sul mercato della cura della fertilità, in particolare la strategia di costruire, acquisire e gestire cliniche di fertilità negli Stati Uniti. L’azienda punta ad ampliare l’accesso a servizi e tecnologie riproduttive innovative, in linea con il recente ordine esecutivo presidenziale statunitense volto a ridurre i costi della FIVET e aumentare la disponibilità dei servizi per la fertilità.
INVO Fertility (Nasdaq: NAYA) anunció que comenzará a cotizar bajo el nuevo símbolo 'IVF' el 28 de abril de 2025, tras su decisión estratégica de separar sus negocios de fertilidad y oncología. La compañía, anteriormente conocida como NAYA Biosciences, mantendrá su número CUSIP actual.
El CEO Steve Shum declaró que el nuevo símbolo bursátil refleja su enfoque en el mercado de cuidado de la fertilidad, especialmente su estrategia de construir, adquirir y operar clínicas de fertilidad en Estados Unidos. La empresa busca ampliar el acceso a servicios y tecnologías reproductivas innovadoras, alineándose con la reciente orden ejecutiva presidencial de EE.UU. para reducir los costos de la FIV y aumentar la accesibilidad a los servicios de fertilidad.
INVO Fertility (나스닥: NAYA)는 2025년 4월 28일부터 새로운 심볼 'IVF'로 거래를 시작할 것이라고 발표했습니다. 이는 생식 및 종양 사업부를 분리하기로 한 전략적 결정에 따른 것입니다. 이전에 NAYA Biosciences로 알려졌던 이 회사는 현재의 CUSIP 번호를 유지할 예정입니다.
CEO 스티브 섬은 새로운 티커 심볼이 생식 치료 시장에 집중하고 있음을 반영하며, 특히 미국 내 생식 클리닉을 구축, 인수 및 운영하는 전략을 나타낸다고 밝혔습니다. 회사는 혁신적인 생식 서비스와 기술에 대한 접근성을 확대하는 것을 목표로 하며, 이는 최근 미국 대통령 행정명령인 IVF 비용 절감 및 생식 서비스 접근성 향상과도 부합합니다.
INVO Fertility (Nasdaq : NAYA) a annoncé qu’elle commencera à être cotée sous le nouveau symbole 'IVF' à partir du 28 avril 2025, suite à sa décision stratégique de séparer ses activités de fertilité et d’oncologie. La société, anciennement connue sous le nom de NAYA Biosciences, conservera son numéro CUSIP actuel.
Le PDG Steve Shum a déclaré que le nouveau symbole boursier reflète leur concentration sur le marché des soins en fertilité, en particulier leur stratégie de création, d’acquisition et d’exploitation de cliniques de fertilité aux États-Unis. L’entreprise vise à élargir l’accès à des services et technologies reproductives innovants, en accord avec le récent décret présidentiel américain visant à réduire les coûts de la FIV et à augmenter l’accessibilité aux services de fertilité.
INVO Fertility (Nasdaq: NAYA) gab bekannt, dass das Unternehmen ab dem 28. April 2025 unter dem neuen Symbol 'IVF' gehandelt wird, nachdem es sich strategisch entschieden hat, seine Fertilitäts- und Onkologiegeschäfte zu trennen. Das Unternehmen, früher bekannt als NAYA Biosciences, behält seine aktuelle CUSIP-Nummer bei.
CEO Steve Shum erklärte, dass das neue Börsensymbol ihren Fokus auf den Markt für Fertilitätsbehandlungen widerspiegelt, insbesondere ihre Strategie, Fruchtbarkeitskliniken in den USA aufzubauen, zu erwerben und zu betreiben. Das Unternehmen strebt an, den Zugang zu innovativen reproduktiven Dienstleistungen und Technologien zu erweitern, im Einklang mit der jüngsten US-Präsidialverordnung zur Senkung der IVF-Kosten und zur Erhöhung der Zugänglichkeit von Fruchtbarkeitsdiensten.
- Strategic focus on high-growth fertility care market
- Alignment with favorable government policy supporting IVF accessibility
- Clear business direction through separation of fertility and oncology divisions
- None.
SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol “IVF” at the market open on April 28, 2025.
The CUSIP number for the Company's common stock will remain unchanged.
The symbol change follows the Company’s announcement on April 14, 2025, regarding the strategic decision to separate its fertility and oncology businesses into distinct operations.
“Our new Nasdaq ticker symbol of ‘IVF’ reflects our go-forward business concentration on the fertility care market,” commented Steve Shum, CEO of INVO Fertility. “This change underscores our strategic focus on building, acquiring and operating fertility clinics in the United States and our focus on innovative reproductive services and technologies. As reinforced by the U.S. President’s recent executive order to reduce the cost of IVF and expand access to fertility services, we look forward to refocusing and scaling our mission of helping people build the families of which they dream.”
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
INVO Fertility
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
When will INVO Fertility (NAYA) start trading under its new IVF ticker symbol?
Why is NAYA Biosciences changing its name and ticker to INVO Fertility (IVF)?
What is INVO Fertility's business strategy following the ticker change from NAYA?
How does the recent U.S. Presidential executive order align with INVO Fertility's mission?
